NMRA
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it...
Read moreDetails
Neumora Stock Hits Record Low on Depression Drug Study Failure
NMRA stock falls after its experimental depression treatment failed to meet the primary and secondary endpoints in the first of...
Read moreDetails
Neumora’s depression drug fails trial, sinking shares
CNBC's Angelica Peebles joins 'Power Lunch' to discuss Neumora's depression drug failing its trial results.
Read moreDetails
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total...
Read moreDetails